AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell

MT Newswires Live06-08

AIM ImmunoTech (AIM) said Monday that its metastatic pancreatic cancer drug Ampligen has shown "positive progress" in an ongoing phase 2 study.

According to the company, the study is showing overall median survival of 34.8 months, compared with 12.5 months for historical controls in one group of study patients with a specific immune marker.

The specific indication for the trial is patients with stable disease after Folfirinox standard of care. The company said it remains on track for a planned December evaluation of the 25-patient trial's primary endpoint of clinical benefit rate at six months.

Shares of AIM rose more than 26% in recent premarket trading Monday.

Price: 0.6520, Change: +0.135, Percent Change: +26.02

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641381482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641381482","market":"nz","top_or_hot":-1,"title":"AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> AIM ImmunoTech (AIM) said Monday that its metastatic pancreatic cancer drug Ampligen has shown \"positive progress\" in an ongoing phase 2 study.</p><p>According to the company, the study is showing overall median survival of 34.8 months, compared with 12.5 months for historical controls in one group of study patients with a specific immune marker.</p><p>The specific indication for the trial is patients with stable disease after Folfirinox standard of care. The company said it remains on track for a planned December evaluation of the 25-patient trial's primary endpoint of clinical benefit rate at six months.</p><p>Shares of AIM rose more than 26% in recent premarket trading Monday.</p><p>Price: 0.6520, Change: +0.135, Percent Change: +26.02</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-08 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AIM ImmunoTech (AIM) said Monday that its metastatic pancreatic cancer drug Ampligen has shown \"positive progress\" in an ongoing phase 2 study.</p><p>According to the company, the study is showing overall median survival of 34.8 months, compared with 12.5 months for historical controls in one group of study patients with a specific immune marker.</p><p>The specific indication for the trial is patients with stable disease after Folfirinox standard of care. The company said it remains on track for a planned December evaluation of the 25-patient trial's primary endpoint of clinical benefit rate at six months.</p><p>Shares of AIM rose more than 26% in recent premarket trading Monday.</p><p>Price: 0.6520, Change: +0.135, Percent Change: +26.02</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGS","symbol_name":"Progress Software Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641381482","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641381482","pubTimestamp":1780923719,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AIM ImmunoTech  said Monday that its metastatic pancreatic cancer drug Ampligen has shown \"positive progress\" in an ongoing phase 2 study.According to the company, the study is showing overall median survival of 34.8 months, compared with 12.5 months for historical controls in one group of study patients with a specific immune marker.The specific indication for the trial is patients with stable disease after Folfirinox standard of care. The company said it remains on track for a planned December evaluation of the 25-patient trial's primary endpoint of clinical benefit rate at six months.Shares of AIM rose more than 26% in recent premarket trading Monday.Price: 0.6520, Change: +0.135, Percent Change: +26.02","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRGS":"Progress Software Corporation","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","AIM":"AIM ImmunoTech Inc.","BK7064":"综合支持服务","BK4557":"大麻股","BK4097":"系统软件","BK4139":"生物科技","AIM.AU":"Ai-Media Technologies Ltd"},"translate_title":"AIM ImmunoTech表示胰腺癌药物在2期研究中显示出“积极进展”；盘前股价上涨","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM":1.5,"PRGS":1.5,"AIM.AU":1},"content_text":"AIM ImmunoTech (AIM) said Monday that its metastatic pancreatic cancer drug Ampligen has shown \"positive progress\" in an ongoing phase 2 study.According to the company, the study is showing overall median survival of 34.8 months, compared with 12.5 months for historical controls in one group of study patients with a specific immune marker.The specific indication for the trial is patients with stable disease after Folfirinox standard of care. The company said it remains on track for a planned December evaluation of the 25-patient trial's primary endpoint of clinical benefit rate at six months.Shares of AIM rose more than 26% in recent premarket trading Monday.Price: 0.6520, Change: +0.135, Percent Change: +26.02","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641381482","isCrawlerRequest":true}